Intro
Contents
1: Epidemiology of Bone and Soft Tissue Sarcomas
1.1 Introduction
1.2 Descriptive Epidemiology
1.2.1 Osteosarcoma
1.2.2 Ewing Sarcoma
1.2.3 Rhabdomyosarcoma (RMS)
1.2.4 Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
1.3 Environmental (Non-genetic) Risk Factors
1.3.1 Osteosarcoma
1.3.1.1 Growth and Development
1.3.1.2 Exogenous Exposures
1.3.2 Ewing Sarcoma
1.3.3 RMS
1.3.4 NRSTS
1.4 Germline Genetic Risk Factors
1.4.1 Osteosarcoma
1.4.2 Ewing Sarcoma
1.4.3 RMS
1.4.4 NRSTS
1.5 Conclusion

2.3.1 Pathology
2.3.2 Biology
2.4 Non-rhabdomyosarcoma Soft Tissue Sarcomas
2.4.1 Alveolar Soft Part Sarcoma
2.4.1.1 Pathology
2.4.1.2 Biology
2.4.2 Clear Cell Sarcoma of Soft Tissue
2.4.2.1 Pathology
2.4.2.2 Biology
2.4.3 Desmoid Tumor
2.4.3.1 Pathology
2.4.3.2 Biology
2.4.4 Desmoplastic Small Round Cell Tumor
2.4.4.1 Pathology
2.4.4.2 Biology
2.4.5 Malignant Peripheral Nerve Sheath Tumor
2.4.5.1 Pathology
2.4.5.2 Biology
2.4.6 Synovial Sarcoma
2.4.6.1 Pathology
2.4.6.2 Biology
2.4.7 Malignant Rhabdoid Tumor

2.4.7.1 Pathology
2.4.7.2 Biology
2.4.8 NTRK-Fusion Sarcomas
2.4.8.1 Pathology
2.4.8.2 Biology
References
3: Staging and Imaging of Sarcoma
3.1 Staging of RMS and NRSTS
3.2 Staging of Nonrhabdomyosarcomatous Soft Tissue Tumors (NRSTS)
3.3 Staging of Bone Sarcomas
3.4 Imaging and Staging Procedures
References
4: Multi-institutional Trials for Patients with Rhabdomyosarcoma: Lessons from North American Studies from 1967 Through 1997
4.1 Introduction
4.2 The First 30 Years, 1970-2000
4.2.1 The IRS Era, 1972-1997
References

5: Treatment of Rhabdomyosarcoma
5.1 Introduction
5.2 Initial Evaluation
5.3 Treatment Assignment
5.4 Treatment
5.4.1 North American Perspective
5.4.2 European Perspective
5.5 Future Directions
References
6: Current Approaches to Therapy: Soft Tissue Sarcomas Other than Rhabdomyosarcoma in Children and Adolescents
6.1 Introduction
6.2 Local Therapy
6.2.1 Surgery
6.2.2 Radiotherapy
6.3 Conventional Chemotherapy
6.4 Specific Therapy for Diseases
6.4.1 Synovial Sarcoma